A PKM2 clinical trial has shown that inhibiting PKM2 significantly enhances the sensitivity of advanced bladder cancer cells to cisplatin, leading to increased apoptosis and reduced cell proliferation. This evidence concerns the gene PKM and urinary bladder cancer.